MDS (Myelodysplastic Syndrome) Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about MDS (Myelodysplastic Syndrome) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 1Phase 2

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting
Phase 1

Romiplostim N01 for Platelet Recovery After Haploidentical HSCT

Acute Myeloid LeukemiaHSCTMDS (Myelodysplastic Syndrome)+1 more
First Affiliated Hospital of Zhejiang University130 enrolled1 locationNCT07321626
Recruiting
Phase 1

A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

AMLMDSLeukemia+2 more
Cullgen (Shanghai),Inc45 enrolled3 locationsNCT07347171
Recruiting
Not Applicable

Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation

AML (Acute Myelogenous Leukemia)ALL (Acute B-Lymphoblastic Leukemia)MDS (Myelodysplastic Syndrome)
Institute of Hematology & Blood Diseases Hospital, China36 enrolled1 locationNCT07297576
Recruiting
Phase 1Phase 2

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, RefractoryMDS (Myelodysplastic Syndrome)
ARCE Therapeutics, Inc.49 enrolled3 locationsNCT06680752
Recruiting
Phase 1Phase 2

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 2

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

MDS (Myelodysplastic Syndrome)Acute Myeloid LeukaemiaMPN (Myeloproliferative Neoplasms)
Istituto Clinico Humanitas42 enrolled2 locationsNCT06892223